

products and services 2003

CHARLES RIVER
LABORATORIES

RESEARCH MODELS

SERVICES FOR RESEARCH MODELS

DISCOVERY AND DEVELOPMENT SERVICES

BIOPHARMACEUTICAL SERVICES

IN VITRO DETECTION SYSTEMS

RESEARCH MODELS :: HYBRID MICE

Ordering Information

Outbred Rats

Inbred Rats

Outbred Mice

Inbred Mice

Hybrid Mice

- B6C3F1 Mice
- BDF1 Mice
- CDF1 Mice
- CB6F1 Mice

Immunodeficient Mice

Transgenic Models


Outbred Hamsters/
Guinea Pigs/Gerbils/
Rabbits

Conscious Rats

Disease Models

Surgical Services

SPF Eggs




CDF1 Mice

| Weight in Grams | MALE | | FEMALE | |
|-----------------|------------------------------|-------|-------------------------|-------|
| | Approximate Age in Days | Price | Approximate Age in Days | Price |
| Up to 12 | Up to 23 | 10.95 | Up to 23 | 12.00 |
| 13-15 | 24-27 | 12.65 | 24-29 | 13.60 |
| 16-18 | 28-32 | 13.50 | 30-44 | 14.55 |
| 19-21 | 33-42 | 14.35 | 45-70 | 15.65 |
| 22-24 | 43-63 | 16.60 | 71-91 | 17.90 |
| 25 plus | Prices upon request | | Prices upon request | |
| | Littermates 21 days old only | | 18.05 | 18.05 |

TO OR
1.800.I

NOMENCLATURE CD2F1/CrlBR ORIGIN A cross between female BALB/cAnNCrlBR x male DBA/2NCrlBR. COAT COLOR Brown.



[Return to Top](#)

[Home :: Research Models :: Services for Research Models](#)

[Discovery and Development Services :: Biopharmaceutical Services](#)

[In Vitro Detection Systems :: References :: Search Catalog :: Contents](#)

[CRL Main Site](#)

© Copyright 2003 Charles River Laboratories, Incorporated



Your Discoveries
Begin with Us.TM

Search: Choose a pr

[Home](#) | [Ordering Info](#) | [Technical Help](#) | [About ATCC](#) | [Contact Us](#)

Search

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's [Material Transfer Agreement](#).

Customers in Europe, Australia, Japan, Korea, New Zealand and Taiwan must contact a [local distributor](#) for pricing information and to place an order for ATCC cultures and products.

| Cell Lines | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ATCC Number: CCL-219 | Price: \$215.00 |
| Order this Item | |
| Designation: L1210 | Depositors: EM Jensen |
| Biosafety Level: 1 | Shipped: frozen |
| Medium & Serum: See Propagation | Growth Properties: suspension |
| Organism: <i>Mus musculus</i> (mouse) | Morphology: lymphoblast |
| Tissue: lymphocytic leukemia | |
| Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | |
| <u>Related Cell Culture Products</u> | |
| Comments: | Tested and found negative for ectromelia virus (mousepox). The line was established from a tumor in female #234 that developed following skin paintings with 0.2% methylcholanthrene in ether. [22513] |
| Tumorigenic: | yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
| Reverse Transcript: | positive |
| Strain: | DBA subline 212 |
| Age Stage: | 8 months |
| Gender: | from female organisms(s) |
| Passage submitted to the ATCC: | 377 |
| Propagation: | ATCC medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; horse |

| | |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | serum, 10% - OR - Fischer's medium, 90%; horse serum, 10% |
| Subculturing: | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp4 viable cells/ml. |
| Fluid Renewal: | Add fresh medium (20% to 30% by volume) every 2 to 4 days |
| Doubling Time: | 8 to 10 hrs |
| References: | <p><u>22513</u>: J. Natl. Cancer Inst. 10: 179-192, 1949.</p> <p><u>26055</u>: J. Natl. Cancer Inst. 36: 405-421, 1966.</p> <p><u>26056</u>: Cancer Chemother. Rep. 51: 451-453, 1967.</p> <p><u>32923</u>: Young SW , et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 93: 6610-6615, 1996.</p> <p>PubMed: 8692865</p> |

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only. They are not intended for use in humans.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will be applied to most cultures for nonprofit institutions in the United States and Canada. Cultures that are ordered as test tubes or flasks will carry an additional laboratory fee. Fees for permits, shipping, and handling may apply.


You may continue your word search in Cell Lines by typing in your search criteria below or returning to the [Cell Lines menu](#). To search another product line, choose one from the dropdown box at the top. For complex searches using boolean operators, the following characters must be used: & (for AND), | (for OR), ^ (for AND NOT). An asterisk (*) is used as the wildcard. For more information please review the [Search Help](#).

For query options, please read the [search help](#).

Home Page Archive

[Home](#) [Ordering Info](#) [Technical Help](#) [About ATCC](#) [Contact Us](#)
[Privacy Policy](#) [Terms of Use](#) [ATCC MTA](#)

© 2003 American Type Culture Collection (ATCC).
All rights reserved.



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

 for



Limits

Preview/Index

History

Clipboard

Details

About Entrez

 Display
 Abstract

Show: 20 Sort

Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

 1: Blood 1990 Oct 1;76(7):1308-14

Related Articles, Link

Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1.

Stein J, Borzillo GV, Rettenmier CW.

Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN.

Secreted forms of macrophage colony-stimulating factor (M-CSF or CSF-1) are generated by proteolytic cleavage of membrane-bound glycoprotein precursors. Alternatively spliced transcripts of the human CSF-1 gene encode at least two different transmembrane precursors that are differentially processed in mammalian expression systems. The larger precursor rapidly undergoes proteolysis to yield the secreted growth factor and does not give rise to forms of CSF-1 detected on the cell surface. By contrast, the smaller human CSF-1 precursor is stably expressed on the plasma membrane where it is inefficiently cleaved to release a soluble molecule. To determine whether the smaller precursor is biologically active on the cell surface, mouse NIH-3T3 fibroblasts expressing the different forms of human CSF-1 were killed by chemical fixation and tested for their ability to support the proliferation of cells that require this growth factor. Only fixed cells expressing human CSF-1 precursors on their surface stimulated the growth in vitro of a murine macrophage cell line or normal mouse bone marrow-derived mononuclear phagocytes. The ability of these nonviable fibroblasts to induce the proliferation of CSF-1-dependent cells was not mediated by release of soluble growth factor, required direct contact with the target cells, and was blocked by neutralizing antiserum to CSF-1. These results demonstrate that the cell surface form of the human CSF-1 precursor is biologically active and indicate that plasma membrane-bound growth factors can functionally interact with receptor-bearing targets by direct cell-cell contact.

PMID: 2145044 [PubMed - indexed for MEDLINE]

 Display
 Abstract

Show: 20 Sort

Text





National
Library
of Medicine

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Dev Comp Immunol 1995 May-Jun;19(3):261-77

Related Articles, Link

The identification of the neonatal NBXFO hybridoma cell and its mediator.

Jadus MR, Irwin MR, Barton BE, Irwin MC, Wepsic HT.

Department of Laboratory Service, Veterans Affairs Medical Center, Long Beach, CA 90822, USA.

The neonatal spleen:myeloma hybridoma cell, NBXFO, with immunosuppressive properties supported rodent hematopoietic colony formation. We identified this hybridoma to be an undifferentiated fibroblast that produced macrophage colony-stimulating factor (M-CSF). The bone marrow cells that grew in the presence of the NBXFO supernate were macrophages and were immunosuppressive towards lymphocytes. Neutralizing anti-M-CSF antibody partially inhibited the actions of the neonatal splenic suppressor cells. Neonatal splenocytes, but not the other parental cell line, FO, induced macrophage colony formation, possessed surface-associated M-CSF, and possessed M-CSF-specific transcripts. Therefore, we believe that the M-CSF-producing phenotype was contributed by a fibroblastic stromal cell and that these stromal cells could be responsible for the *in situ* generation of neonatal splenic suppressor cells.

PMID: 8595824 [PubMed - indexed for MEDLINE]

Show: 20

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



Your Discoveries
Begin with Us.™

Search: - Choose a pr

[Home](#) | [Ordering Info](#) | [Technical Help](#) | [About ATCC](#) | [Contact Us](#)

Search

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's [Material Transfer Agreement](#).

Customers in Europe, Australia, Japan, Korea, New Zealand and Taiwan must contact a [local distributor](#) for pricing information and to place an order for ATCC cultures and products.

Cell Lines

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ATCC Number: CCL-219 | Price: \$215.00 |
| Order this item | |
| Designation: L1210 | Depositors: EM Jensen |
| Biosafety Level: 1 | Shipped: frozen |
| Medium & Serum: See Propagation | Growth Properties: suspension |
| Organism: <i>Mus musculus</i> (mouse) | Morphology: lymphoblast |
| Tissue: lymphocytic leukemia | |
| Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | |
| <i>Related Cell Culture Products</i> | |
| Comments: | Tested and found negative for ectromelia virus (mousepox). The line was established from a tumor in female #234 that developed following skin paintings with 0.2% methylcholanthrene in ether. [22513] |
| Tumorigenic: | yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
| Reverse Transcript: | positive |
| Strain: | DBA subline 212 |
| Age Stage: | 8 months |
| Gender: | from female organisms(s) |
| Passage submitted to the ATCC: | 377 |
| Propagation: | ATCC medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; horse |

| | |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | serum, 10% - OR - Fischer's medium, 90%; horse serum, 10% |
| Subculturing: | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp4 viable cells/ml. |
| Fluid Renewal: | Add fresh medium (20% to 30% by volume) every 2 to 4 days |
| Doubling Time: | 8 to 10 hrs |
| References: | <p><u>22513</u>: J. Natl. Cancer Inst. 10: 179-192, 1949.</p> <p><u>26055</u>: J. Natl. Cancer Inst. 36: 405-421, 1966.</p> <p><u>26056</u>: Cancer Chemother. Rep. 51: 451-453, 1967.</p> <p><u>32923</u>: Young SW , et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 93: 6610-6615, 1996.</p> <p>PubMed: <u>8692865</u></p> |

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only. They are not intended for use in humans.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will be applied to most cultures for nonprofit institutions in the United States and Canada. Cultures that are ordered as test tubes or flasks will carry an additional laboratory fee. Fees for permits, shipping, and handling may apply.


You may continue your word search in Cell Lines by typing in your search criteria below or returning to the [Cell Lines menu](#). To search another product line, choose one from the dropdown box at the top. For complex searches using boolean operators, the following characters must be used: & (for AND), | (for OR), ^ (for AND NOT). An asterisk (*) is used as the wildcard. For more information please review the [Search Help](#).

For query options, please read the [search help](#).

Home Page Archive

[Home](#) [Ordering Info](#) [Technical Help](#) [About ATCC](#) [Contact Us](#)
[Privacy Policy](#) [Terms of Use](#) [ATCC MTA](#)

© 2003 American Type Culture Collection (ATCC).
All rights reserved.



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search for 

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Show:

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

1: J Natl Cancer Inst 1995 Jun 7;87(11):809-16

Related Articles, Link

Comment in:

- [J Natl Cancer Inst. 1995 Nov 15;87\(22\):1716-7.](#)

Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma.

Walsh P, Dorner A, Duke RC, Su LJ, Glode LM.

(Department of Dermatology), University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver 80262, USA.

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

BACKGROUND: At present, there is no highly effective treatment for metastatic melanoma. Innovative approaches aimed at inducing a more effective immune response against tumors have shown promising results in animal models. One approach involves the genetic modification of tumor cells so that they produce cytokines that stimulate an immune response. **PURPOSE:** The aim of this study was to determine the effectiveness of cytokine gene therapy for metastatic melanoma in a murine melanoma model. **METHODS:** B16F10 murine melanoma cells, which readily metastasize to the lungs, were transduced with a retroviral vector containing genes encoding neomycin resistance and human macrophage colony-stimulating factor (M-CSF). The presence of M-CSF messenger RNA in transduced cells was examined by coupled reverse transcription and polymerase chain reaction. Concentrations of soluble M-CSF in cell culture supernatants were determined by enzyme-linked immunosorbent assays (ELISAs). A clonal cell line, designated N+/CSF+, that expressed and secreted M-CSF was identified. Another clonal cell line, designated N+/CSF-, did not secrete M-CSF at levels detectable by ELISA. B16F10, N+/CSF-, and N+/CSF+ cells, individually or in combination, were injected intravenously or subcutaneously into C57BL/6 mice; we then evaluated the tumorigenicity and metastatic behavior of the cells, as well as the immune responses and survival of the mice. The immune responses assayed were the cytotoxic T lymphocyte (CTL) and peritoneal exudate cell (PEC) tumoricidal activities. **RESULTS:** Injection of B16F10 cells into the tail vein of C57BL/6 mice led to the establishment of lung metastases by week 2 and death by week 8. Injection of the N+/CSF+ or N+/CSF- cells led to the establishment of lung metastases that were detected at 2 and 3 weeks, respectively; however, these metastatic lesions were eliminated, and the animals had

survival rates similar to those of the noninjected control mice. Injection of mice with a mixture of B16F10 and N+/CSF- cells resulted in the development of metastatic disease and 0% survival at 8 weeks, whereas mice that had been given an injection of a mixture of B16F10 and N+/CSF+ cells had an 80% survival rate at 8 weeks and survived at least two times longer ($F = .007$). The CTL and PEC tumoricidal activities in animals given an injection of N+/CSF+ cells suggested that monocytes and lymphocytes were responsible for the observed antitumor response. CONCLUSION: These findings suggest that the expression of M-CSF by genetically modified melanoma cells caused an effective antitumor immune response in host C57BL/6 mice and, thus, prolonged survival over that observed in the control mice.

PMID: 7791230 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

May 20 2003 11:14:4



National
Library
of Medicine

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search for

Limits

Preview/Index

History

Clipboard

Details

About Entrez

 Display Abstract Show: Sort Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

 1: Eur J Immunol 1993 Jan;23(1):186-90

Related Articles, Link

Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression.

Dorsch M, Hock H, Kunzendorf U, Diamantstein T, Blankenstein T.

Institut fur Immunologie, Universitatsklinikum Steglitz, Freie Universität Berlin, FRG.

In order to analyze the effect of a high local concentration of macrophage colony-stimulating factor (M-CSF; CSF-1) on tumor growth, the plasmacytoma cell line J558L was transfected with the human M-CSF gene and injected into syngeneic BALB/c mice. In contrast to the parental tumors, M-CSF transfectants were heavily infiltrated by macrophages as evidenced by immunohistochemistry with antibodies to Mac-1 and Mac-3 and by isolation of the macrophages from the tumor. Nevertheless, tumor growth was only slightly affected by M-CSF and M-CSF-producing cells grew as tumor in all cases. The growth retardation of M-CSF-producing cells varied depending on the experiment and seemed to be due to an indirect effect because the growth rate of the cells in vitro had not changed upon gene transfer. Attempts to activate the tumor-infiltrating macrophages for tumor suppression by systemic application of interferon-gamma and/or lipopolysaccharide were not successful. Altogether, our results suggest that M-CSF is a potent chemoattractant for macrophages in vivo but alone is not sufficient to activate these macrophages for tumoricidal activity.

PMID: 8419170 [PubMed - indexed for MEDLINE]

 Display Abstract Show: Sort Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)